NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines that can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease.

Pharmaceutical

NeuBase Therapeutics

Dietrich A. Stephan

Nathan T.

Lindsey Spiker

Steven Murphy

Kayla Williams

Chelsea Martinez

Barry Badeau

William Riedl

Lydia(Lyuqin) Chen

Jeremy Gleaton

Sally Edmonds

Ranajoy Sarkar

Jonathan Leung

John J. Thomas

Dov Goldstein

Jessica Balogh

Eric Richman

Todd P. Branning

Sandra Rojas-Caro

The board of directors at NeuBase Therapeutics has a history of experience in the industry, academia, and nonprofit sectors. Directors have various educational backgrounds in marketing, molecular biology, cancer biology, and more from institutions such as San Jose State University, California State University - East Bay, UC Irvine, and MIT. Furthermore, members of the board have served in high-level positions at companies such as 4M Genomics Inc., The ChangeBox Foundation, and Howard Hughes Medical Institute.

Board of Directors

Leadership Team

CEO and Executive Team

Board of Directors

About

Team members

Other teams at NeuBase Therapeutics

Leadership Team

CEO and Executive Team